Immune and non-immune cell subtypes identify novel targets for prognostic and therapeutic strategy: A study based on intratumoral heterogenicity analysis of multicenter scRNA-seq datasets in lung adenocarcinoma.

Front Immunol · 2022 · PMC9723329 · PMID 36483553

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

might be significantno p-value reported

Hence our data further confirmed that CTLA-4 and PD-1/PD-L1 might be significant targets for immune therapies in LUAD.

also in 2,435 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.